These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18456658)

  • 1. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor.
    Gakovic M; Ragimbeau J; Francois V; Constantinescu SN; Pellegrini S
    J Biol Chem; 2008 Jul; 283(27):18522-9. PubMed ID: 18456658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.
    Shide K; Shimoda K; Kamezaki K; Kakumitsu H; Kumano T; Numata A; Ishikawa F; Takenaka K; Yamamoto K; Matsuda T; Harada M
    Leuk Res; 2007 Aug; 31(8):1077-84. PubMed ID: 17011030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2, the JAK2 V617F mutant and cytokine receptors.
    Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
    Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
    Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN
    J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase.
    Dondi E; Pattyn E; Lutfalla G; Van Ostade X; Uzé G; Pellegrini S; Tavernier J
    J Biol Chem; 2001 Dec; 276(50):47004-12. PubMed ID: 11602573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.
    Lu X; Huang LJ; Lodish HF
    J Biol Chem; 2008 Feb; 283(9):5258-66. PubMed ID: 18158285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway.
    Wei S; Luo C; Yu S; Gao J; Liu C; Wei Z; Zhang Z; Wei L; Yi B
    Exp Cell Res; 2017 Dec; 361(2):342-352. PubMed ID: 29102603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.
    Andrés RM; Hald A; Johansen C; Kragballe K; Iversen L
    Exp Dermatol; 2013 May; 22(5):323-8. PubMed ID: 23614738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
    Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
    J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and biologically significant interactions of human herpesvirus 8 interferon regulatory factor 1 with STAT3 and Janus kinase TYK2.
    Yang Z; Xiang Q; Nicholas J
    PLoS Pathog; 2023 Nov; 19(11):e1011806. PubMed ID: 37983265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
    Velusamy T; Kiel MJ; Sahasrabuddhe AA; Rolland D; Dixon CA; Bailey NG; Betz BL; Brown NA; Hristov AC; Wilcox RA; Miranda RN; Medeiros LJ; Jeon YK; Inamdar KV; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Dec; 124(25):3768-71. PubMed ID: 25349176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the functional binding sites of interleukin 12 receptor β1 and interleukin 23 receptor to Janus kinases.
    Floss DM; Klöcker T; Schröder J; Lamertz L; Mrotzek S; Strobl B; Hermanns H; Scheller J
    Mol Biol Cell; 2016 Jul; 27(14):2301-16. PubMed ID: 27193299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
    Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
    Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
    Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
    Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.